Interferon alfa down-regulates CD81 in patients with chronic hepatitis C

Hepatology

Volumn 33, Issue 6, 2001, Pages 1518-1526

  Kronenberger, Bernd ^a   Rüster, Brigitte ^a   Elez, Robert ^a   Weber, Stephan ^a   Piiper, Albrecht ^a   Lee, Jung Hun ^a   Roth, W Kurt ^b   Zeuzem, Stefan ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b Institut fur Transfusionsmedizin und Immunhamatologie   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CD81 ANTIGEN; VIRUS GLYCOPROTEIN;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CELL SURFACE; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; VIRUS ENVELOPE;

EID: 0034982354     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2001.24668     Document Type: Article

References (48)

1. Hepatitis C virus infection is associated with the development of hepatocellular carcinoma
2. The natural history of community-acquired hepatitis C in the United States
3. Interferon alfa therapy in patients with chronic hepatitis C and persistently normal aminotransferase activity
4. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
5. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
6. Intrahepatic hepatitis C virus-specific cytotoxic T lymphocyte activity and response to interferon alfa therapy in chronic hepatitis C
7. Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivo
8. Hepatitis C virus dynamics in vivo: Effect of ribavirin and interferon alfa on viral turnover
9. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy
10. Clinical implications of hepatitis C viral kinetics
11. Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: A comparison with ribavirin and demonstration of antiviral additivity with alpha interferon
12. Possible mechanisms of action and reasons for failure of antiviral therapy in chronic hepatitis C
13. Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fgl2 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response
14. Ribavirin polarizes human T cell responses towards a type 1 cytokine profile
15. Normal development but differentially altered proliferative responses of lymphocytes in mice lacking CD81
16. Binding of hepatitis C virus to CD81
17. Identification of amino acid residues in CD81 critical for interaction with hepatitis C virus envelope glycoprotein E2
18. Structure-function analysis of hepatitis C virus envelope-CD81 binding
19. Functional analysis of cell surface-expressed hepatitis C virus E2 glycoprotein
20. The role of the hepatitis C virus glycoproteins in infection
21. Functional characterization of intracellular and secreted forms of a truncated hepatitis C virus E2 glycoprotein
22. Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81
23. Evaluation of hepatitis C virus glycoprotein E2 for vaccine design: An endoplasmic reticulum-retained recombinant protein is superior to secreted recombinant protein and DNA-based vaccine candidates
24. Selective enrichment of tetraspan proteins on the internal vesicles of multivesicular endosomes and on exosomes secreted by human B-lymphocytes
25. A retention signal necessary and sufficient for endoplasmic reticulum localization maps to the transmembrane domain of hepatitis C virus glycoprotein E2
26. Effects of proinflammatory cytokines on cultivated primary human hepatocytes. Fluorometric measurement of intercellular adhesion molecule-1 and human leukocyte antigen-A, -B, -C, and -DR expression
27. The growing family of interferon regulatory factors
28. Interferon regulatory factors: The next generation
29. Interferon-alpha2b/ribavirin (Rebetron) treatment for chronic hepatitis C - Population pharmacokinetics and pharmacodynamics of ribavirin
30. Dedifferentiation of human hepatocytes by extracellular matrix proteins in vitro: Quantitative and qualitative investigation of cytokeratin 7, 8, 18, 19 and vimentin filaments
31. Peg-interferon alpha-2b: Pharmacokinetics, pharmacodynamics, safety and preliminary efficacy data
32. A branched methoxy 40 kDa polyethylene glycol (PEG) moiety optimizes the pharmacokinetics (PK) of peg interferon alpha-2a (PEG-IFN) and may explain its enhanced efficacy in chronic hepatitis C
33. Is an à la carte combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C?
34. Genotype and viral load as prognostic indicators in the treatment of hepatitis C
35. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon-alpha-2a
36. Detection of replicative form of hepatitis C virus RNA in peripheral blood mononuclear cells
37. Quantification of hepatitis C virus-infected peripheral blood mononuclear cells by in situ reverse transcriptase-polymerase chain reaction
38. Specific detection of hepatitis C virus minus strand RNA in hematopoietic cells
39. Hepatitis C virus RNA in peripheral blood mononuclear cells: Comparing acute and chronic hepatitis C virus infection
40. Recombinant human monoclonal antibodies against different conformational epitopes of the E2 envelope glycoprotein of hepatitis C virus that inhibit its interaction with CD81
41. Characterization of modified hepatitis C virus E2 proteins expressed on the cell surface
42. Hepatitis C virus glycoprotein E2 binding to CD81: The role of E1E2 cleavage and protein glycosylation in bioactivity
43. Binding of hepatitis C virus E2 glycoprotein to CD81 does not correlate with species permissiveness to infection
44. Allergen-induced airway hyperreactivity is diminished in CD81-deficient mice
45. CD81 on B cells promotes interleukin 4 secretion and antibody production during T helper type 2 immune responses
46. CD81 (TAPA-1): A molecule involved in signal transduction and cell adhesion in the immune system
47. Hepatitis C virus is detected in a monocyte/macrophage subpopulation of peripheral blood mononuclear cells of infected patients
48. Hepatitis C virus persistence in human hematopoietic cells injected into SCID mice